Dietary supplementation with cis-9,trans-11 conjugated linoleic acid and aortic stiffness in overweight and obese adults.

Study answer

What this study found

CLA supplementation did not improve aortic stiffness or cardiovascular risk factors. The primary endpoint, change in aortic PWV, was 0.00 ± 0.07 m/s in the CLA group versus 0.09 ± 0.06 m/s with placebo, with a between-group difference of -0.09 (-0.29, 0.09; P = 0.31). There were also no significant between-group differences in central or peripheral blood pressure, weight, BMI, waist measures, plasma lipids, glucose, insulin, HOMA-IR, or hs-CRP. Safety findings were similar overall, with 188 adverse events in 102 CLA participants versus 170 in 94 placebo participants (P = 0.59), and serious…

Study & population

Single-center randomized placebo-controlled trial in apparently healthy overweight and obese adults in Utrecht, Netherlands.

Intervention

Adults in the active arm received four 1 g capsules daily of c9,t11 conjugated linoleic acid (CLA) oil for 6 months, for a total dose of 4 g/day.

Key limitation

The study duration was only 6 months, and the analyzed active-arm sample was smaller than the randomized sample.

View full study detailsView sourceOpen PDF

Original abstract